Rivo has applied for a European clinical trial for a novel dual-targeting siRNA SR122 for mixed and severe dyslipidemia, further strengthening its footprint in the area of dyslipidemia. Company announcement - FT.com.
Rivo has applied for a European clinical trial for a novel dual-targeting siRNA SR122 for mixed and severe dyslipidemia, further strengthening its footprint in the area of dyslipidemia. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in